Effectiveness of two same-manufacturer intravenous immunoglobulin for Kawasaki disease

Background: To investigate whether two brands of intravenous immunoglobulin (IVIG) from the same manufacturer lead to varied effects when administered to patients with Kawasaki disease. (KD) Methods: Clinical characteristics, laboratory data, IVIG response, and coronary arteries change were analyzed between two groups. Results: We included 158 KD cases. The mean age at KD diagnosis was 23 ± 1.39 (range, 2–95) months. In the first IVIG course, 18 (11.4 %) patients were unresponsive. TBSF (brand T) and Privigen (brand P) were administered to 94 and 64 patients, respectively. The brand P group had a significantly longer fever (P